SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer

Introduction Most patients with advanced gallbladder cancer are treated with multiagent chemotherapy. Immune checkpoint inhibitors offer the possibility of a durable response with less toxicity. This prospective, multicenter, open‐label study was designed to evaluate the anticancer activity of nivol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Jg. 130; H. 17; S. 2918 - 2927
Hauptverfasser:	Patel, Sandip P., Guadarrama, Elizabeth, Chae, Young Kwang, Dennis, Michael J., Powers, Benjamin C., Liao, Chih‐Yi, Ferri, William A., George, Thomas J., Sharon, Elad, Ryan, Christopher W., Othus, Megan, Lopez, Gabby, Blanke, Charles D., Kurzrock, Razelle
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Wiley Subscription Services, Inc 01.09.2024
Schlagworte:	Adult Aged Aged, 80 and over Anemia Anorexia Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Aspartate aminotransferase biliary tract cancer Chemotherapy Cholangiocarcinoma CTLA-4 Antigen - antagonists & inhibitors Eating disorders Effectiveness Female Gallbladder Gallbladder cancer Gallbladder Neoplasms - drug therapy Gallbladder Neoplasms - pathology Humans immune checkpoint inhibitor Immune checkpoint inhibitors Immune Checkpoint Inhibitors - administration & dosage Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immunohistochemistry Immunotherapy ipilimumab Ipilimumab - administration & dosage Ipilimumab - adverse effects Ipilimumab - therapeutic use Male Middle Aged Monoclonal antibodies Multiagent systems nivolumab Nivolumab - administration & dosage Nivolumab - adverse effects Nivolumab - therapeutic use Programmed Cell Death 1 Receptor - antagonists & inhibitors Progression-Free Survival Prospective Studies Response rates Sepsis Survival Targeted cancer therapy Toxic diseases Toxicity biliary tract cancer immune checkpoint inhibitor nivolumab ipilimumab
ISSN:	0008-543X, 1097-0142, 1097-0142
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!